"With the goal of advancing care and providing innovative treatment approaches for people living with rare haematologic diseases, we are excited to share data at this year's virtual ISTH," said
Real-world outcomes to be presented for Alprolix® and Elocta®
Data will be presented on Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), both extended half-life factor therapies for people with haemophilia A and
Oral presentation
- First Interim Analysis of a 24-month French, Multicentre, Prospective, Non-interventional Study Evaluating the Real-world Usage and Effectiveness of the Extended Half-life Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B (B-SURE). Session: Hemophilia: Real World Data.
Sunday, July 18 (11:00-12:00 EST ). # OC 08.1.
ePosters
- Interim Analysis of the PREVENT Study: Real World Prospective Data from Children and Adolescents with Haemophilia A or B Treated with Recombinant Factor VIII Fc (rFVIIIFc) or Recombinant Factor IX Fc (rFIXFc) Poster #PB0506.
-
Final Results of ReITIrate - A Prospective Study of Rescue Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc (rFVIIIFc) in Patients who Have Failed Previous ITI Attempts. Poster #PB0522. Joint with
Sanofi . -
Real-world Usage of rFIXFc in
Sweden : A Report from the Swedish National Registry for Bleedings Disorders. Poster #PB0551. -
B-MORE, Baseline Analysis from a 24-month Prospective, Non-interventional, Multicentre Study on Real-world Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia
B. Poster #PB0552.
Real-world data for Doptelet® in the treatment of chronic immune thrombocytopenia
Sobi will present three abstracts on the use of Doptelet (avatrombopag) in chronic immune thrombocytopenia (ITP), including real-world data from
Oral presentation
- Durability of Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-hoc Results from the Phase 3 Core and Open-label Extension Study.
Wednesday, July 21 (13:00-14:00 EST ). Poster #OC 72.4.
ePosters
- Length of Thrombopoietin Receptor Agonist (TPO-RA) Treatment and Persistence in Immune Thrombocytopenia (ITP): Real World United States Claims Analyses. Poster #PB0819.
-
Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia: A Multicenter Study of
U.S. ITP Referral Centers. Poster #PB0823.
Effect on fatigue in patients with paroxysmal nocturnal haemoglobinuria (PNH)
Data will be presented on the effect of treatment with pegcetacoplan on fatigue in patients on pegcetacoplan monotherapy and patients switching from eculizumab to pegcetacoplan.
live e-poster
- Clinically Meaningful and Long-Term Improvements in Fatigue With the C3 Inhibitor Pegcetacoplan In Paroxysmal Nocturnal Hemoglobinuria: Post-Hoc Analyses from the PEGASUS Study Week 48.
Tuesday, July 20 (15:00-16:00 EST ). Poster #LPB0118.
All ePosters will be made available virtually on
About Alprolix®
Alprolix® (eftrenonacog alfa), is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Alprolix is manufactured using a human cell line in an environment free of animal and human additives. Alprolix is approved and marketed by Sobi for the treatment of haemophilia B in the EU,
About Elocta®
Elocta® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology (rFVIIIFc) to prolong circulation in the body. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Elocta is manufactured using a human cell line in an environment free of animal and human additives.
Elocta is approved and marketed by Sobi for the treatment of haemophilia A in the EU,
About the Sobi and
Sobi and
About Doptelet® (avatrombopag)
Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved by the
About pegcetacoplan
Pegcetacoplan is a therapy targeting C3, the central protein in the complement cascade. It acts proximally in the complement cascade controlling both C3b mediated extravascular haemolysis and terminal complement mediated intravascular haemolysis. Pegcetacoplan is being evaluated in several clinical studies across haematology, ophthalmology, nephrology, and neurology. In
About the Sobi and Apellis Collaboration
Sobi and Apellis entered a collaboration to develop and commercialise systemic pegcetacoplan in
About Sobi(TM)
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across
For more information, please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 767 248 830
maria.kruse@sobi.com
1 (Lambert et al. Blood 2017)
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-present-data-at-the-isth-2021-within-rare-haematology-diseases,c3381025
https://mb.cision.com/Main/14266/3381025/1441850.pdf
(c) 2021 Cision. All rights reserved., source